Deciphering novel functions for histone deacetylases in genome maintenance and designing mechanism based therapeutic strategies for cancers
Histone deacetylases (HDACs) are classically connected to transcriptional regulation. However, we previously showed unrecognized functions for mammalian class 1 HDACs (HDACs 1, 2 and 3) in DNA replication, DNA repair and DNA damage response. HDACs are attractive and proven therapeutic targets in cancer therapy as exemplified by the availability of FDA-approved HDIs. However, an FDA-approved HDI is currently not available for treating B-cell malignancies. My lab is focused on understanding functions for individual HDACs in genome stability and applying these mechanistic studies to design novel epigenetic based therapeutic strategies for a subset of hard-to-treat cancers.
Domain 1 - UMR 3347 / U1021 - Normal and pathological signaling